Lee Boram, Lee Hyunwoo, Cho Junhun, Yoon Sang Eun, Kim Seok Jin, Park Woong-Yang, Kim Won Seog, Ko Young Hyeh
Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Department of Health Science and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, South Korea.
Front Oncol. 2021 Mar 11;11:628807. doi: 10.3389/fonc.2021.628807. eCollection 2021.
Primary refractory/relapsed diffuse large B-cell lymphoma (rrDLBCL) is an unresolved issue for DLBCL treatment and new treatments to overcome resistance is required. To explore the genetic mechanisms underlying treatment resistance in rrDLBCL and to identify candidate genes, we performed targeted deep sequencing of 430 lymphoma-related genes from 58 patients diagnosed with rrDLBCL. Genetic alterations found between the initial biopsy and biopsy at recurrence or refractory disease were investigated. The genes most frequently altered (> 20%) were (in decreasing order of frequency) , and . Genes mutation of which in pretreatment sample were associated with poor overall survival included , , , , and ( < 0.05). , , , and were associated with poor progression-free survival ( < 0.05). Most mutations were truncal and were maintained in both the initial biopsy and post-treatment biopsy with high dynamics of subclones. Immune-evasion genes showed increased overall mutation frequency () and variant allele fraction (), and decreased copy number () at the post-treatment biopsy. Using the established mutational profiles and integrative analysis of mutational evolution, we identified information about candidate genes that may be useful for the development of future treatment strategies.
原发性难治性/复发性弥漫性大B细胞淋巴瘤(rrDLBCL)是DLBCL治疗中尚未解决的问题,需要新的治疗方法来克服耐药性。为了探索rrDLBCL治疗耐药的遗传机制并鉴定候选基因,我们对58例诊断为rrDLBCL的患者的430个淋巴瘤相关基因进行了靶向深度测序。研究了初诊活检与复发或难治性疾病活检之间发现的基因改变。最常发生改变(>20%)的基因(按频率降序排列)为 、 和 。预处理样本中发生突变且与总生存期较差相关的基因包括 、 、 、 、 和 (P<0.05)。 、 、 和 与无进展生存期较差相关(P<0.05)。大多数突变是体细胞突变,在初诊活检和治疗后活检中均有保留,亚克隆具有较高的动态变化。免疫逃逸基因在治疗后活检时显示出总体突变频率增加( )、变异等位基因频率增加( )和拷贝数减少( )。利用已建立的突变谱和突变进化的综合分析,我们确定了可能有助于未来治疗策略开发的候选基因信息。